4 / 19
Page 26
Notes:
conferenceseries
.com
Volume 7, Issue 4(Suppl)
J Gastrointest Dig Syst, an open access journal
ISSN: 2161-069X
Gastro Congress 2017
September 11-12, 2017
September 11-12, 2017 | Paris, France
12
th
Euro-Global Gastroenterology Conference
Liver disease and pharmacotherapy for alcoholism
Mike McDonough
Western Hospital, Australia
A
common clinical question to Addiction specialists concerns whether a medication to treat a patient’s alcoholism should be used
and if so, when could such be commenced given the patient has liver disease. Alcohol consumption itself is a principal driver
of alcoholic liver disease and as such, should prompt treatment intervention. While there is a reasonable evidence for medications
that treat alcoholism, very little evidence exists to guide the decision to use such medication in the presence of clinically significant
liver disease. This presentation reviews recent literature on pharmacotherapy for alcohol dependence relating particularly to patients
having comorbid liver disease and alcoholism. It concludes with an outline for a Risk versus Benefit approach to pharmacotherapy
decision-making.
Biography
Mike McDonough an Associate Professor worked for the University of Melbourne in the department of Medicine & Radiology. Now he is working as Medical Director-
Drug health services in Western Health.
michael.mcdonough@wh.org.auMike McDonough, J Gastrointest Dig Syst 2017, 7:4(Suppl)
DOI: 10.4172/2161-069X-C1-052